Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02502890 · ClinicalTrials.gov registry record
Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy
A clinical trial of Asthma, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 208
- Enrollment target
- 9
- Study locations
NCT02502890: Completed study of Asthma, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT02502890 is a study of Asthma that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 208 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02502890, a study of Asthma, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 208 participants
- Enrollment target
- 9
- Study locations
Study Summary
Asthma is a growing problem, especially in children. It causes frequent wheezing, shortness of breath, chest tightness, and cough. A cold that is caused by a virus (viral cold) can sometimes make asthma symptoms worse. This study will help investigators learn about the way colds are related to asthma attacks among children who need higher amounts of medications to control their asthma. Investigators want to learn why viral colds sometimes cause asthma attacks and other times do not by studying the immune system response in samples taken from the nose and blood.
Primary Outcome
Gene expression will be measured by whole transcriptome RNA sequencing.
Conditions Studied
Study Locations (9)
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- Ann and Robert Lurie Children's Hospital of Chicago - Chicago
Massachusetts
- Boston University School of Medicine - Boston
Michigan
- Henry Ford Health System - Detroit
Missouri
- St. Louis Children's Hospital - St Louis
New York
- Columbia University Medical Center - New York
Ohio
- Cincinnati Children's Hospital - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-01 |
What the finished NCT02502890 record still lists
NCT02502890 is an observational study that tracks outcomes without assigning an intervention. The registered 208 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 0 interventions.
NCT02502890 lists 9 locations in 9 states (Colorado, District of Columbia, Illinois).
Frequently Asked Questions
What is clinical trial NCT02502890 about?
NCT02502890 is a clinical study titled "Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy". Asthma is a growing problem, especially in children. It causes frequent wheezing, shortness of breath, chest tightness, and cough. A cold that is caused by a virus (viral cold) can sometimes make asthma symptoms worse. This study will help investigators learn about the way colds are related to asthm...
What is the current status of trial NCT02502890?
This trial is currently completed. The enrollment target is 208 participants. The study started on 2015-10. Estimated completion is 2017-01.
What conditions does trial NCT02502890 study?
This clinical trial studies the following conditions: Asthma.
Who is sponsoring clinical trial NCT02502890?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02502890 being conducted?
This trial has 9 study locations across Colorado, District of Columbia, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02502890's enrollment target sits among peer trials
208 157th of 374 higher than 217 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Innate Immunity in Allergic Asthma
RECRUITING
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
RECRUITING
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465774 · 208 participants
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
- NCT03803332 · 208 participants · NA
A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel
- NCT04732065 · 208 participants · Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- NCT05293756 · 208 participants · NA
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia